Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
PELTHOS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
03.09. | Pelthos Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
02.09. | Oppenheimer initiates Pelthos Therapeutics stock with Outperform rating | 3 | Investing.com | ||
20.08. | Ligand Q1 2025: Umsatz steigt um 46 %, strategische Fusion zu Pelthos angekündigt | 1 | Investing.com Deutsch | ||
20.08. | Ligand Q1 2025 slides: Revenue surges 46%, strategic Pelthos merger announced | 2 | Investing.com | ||
18.08. | Pelthos Therapeutics, Inc.: Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update | 504 | GlobeNewswire (Europe) | Files Quarterly Report on Form 10-Q detailing financial results for legacy operations for the three and six months ended June 30, 2025Strong physician response following successful launch of ZELSUVMI... ► Artikel lesen | |
18.08. | Pelthos Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
13.08. | Pelthos Therapeutics Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
25.07. | Pelthos Therapeutics Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
10.07. | Ligand Pharma Earns Milestone Payment From Pelthos On Commercial Launch Of ZELSUVMI | 379 | AFX News | WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals (LGND) announced that its partner Pelthos Therapeutics Inc. (PTHS) has commercially launched ZELSUVMI or berdazimer topical gel 10.3%, the first... ► Artikel lesen | |
10.07. | Pelthos Therapeutics Launches First At-Home Prescription Gel For Highly Contagious Skin Disease | 1 | Benzinga.com | ||
10.07. | Ligand Pharmaceuticals: Ligand Partner Pelthos Therapeutics Launches ZELSUVMI | 248 | GlobeNewswire (Europe) | JUPITER, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE American: PTHS) has commercially... ► Artikel lesen | |
02.07. | Pelthos Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
02.07. | Ligand, Pelthos Close Merger Deal With Channel's CHRO; To Launch ZELSUVMI In July | 416 | AFX News | WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals Inc. (LGND) and Pelthos Therapeutics Inc. announced Wednesday the closing of the previously announced merger agreement with Channel Therapeutics... ► Artikel lesen | |
02.07. | Ligand schließt Fusion ab, Pelthos bringt Molluscum-Behandlung auf den Markt | 6 | Investing.com Deutsch | ||
02.07. | Ligand completes merger, Pelthos to launch molluscum treatment | 2 | Investing.com | ||
02.07. | Ligand Pharmaceuticals: Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics | 195 | GlobeNewswire (Europe) | Pelthos plans to launch ZELSUVMI for the treatment of Molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, Ligand has invested $18 million in the combined company... ► Artikel lesen | |
27.06. | Channel Therapeutics announces 10-for-1 reverse split ahead of NYSE American uplisting | 2 | Seeking Alpha | ||
27.06. | Channel Therapeutics Corporation: Channel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private Placement | 183 | GlobeNewswire (Europe) | FREEHOLD, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE American: CHRO), an emerging leader in the development of non-opioid pain treatment... ► Artikel lesen | |
14.05. | EXCLUSIVE: Channel Therapeutics Touts Positive Efficacy Results For Eye Treatment Potential In Multiple Preclinical In Vivo Models | 2 | Benzinga.com | ||
13.05. | Channel Therapeutics Corp - 10-Q, Quarterly Report | 1 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 5,818 | -0,34 % | Evotec Aktie: Und nun?- Aixtron, BioNTech, Hensoldt, Knaus Tabbert und Smartbroker im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
VALNEVA | 3,830 | +0,31 % | Valneva: Total-Crash - Aktie zerlegt sich, Ursache sorgt für Aufsehen!!! | ||
MAINZ BIOMED | 1,660 | -3,49 % | Mainz Biomed Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
SUMMIT THERAPEUTICS | 18,940 | +1,83 % | Summit Therapeutics rises as co-CEOs buy nearly $12M worth of company stock | ||
BIONTECH | 82,50 | +0,06 % | BioNTech Aktie: Ist das der Startschuss für den Krebs-Killer aus Mainz? | © Foto: Foto von FRANK MERIÑO auf PexelsDas Warten hat endlich ein Ende. BioNTech schreibt mit seinem Krebsmedikament BNT323 Medizingeschichte.Nach jahrelanger Forschung meldet das Mainzer Unternehmen... ► Artikel lesen | |
ARCELLX | 76,19 | -1,92 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
ADMA BIOLOGICS | 16,110 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
QIAGEN | 38,885 | -0,29 % | QIAGEN N.V.: QIAGEN erhält europäische CE-IVDR-Zertifizierung für das gesamte QIAstat-Dx-Portfolio | Komplettes Portfolio an QIAstat-Dx-Panels ab jetzt CE-IVDR-zertifiziert und damit für den Einsatz in der klinischen syndromischen Testung zugelassen ein klares Bekenntnis zu Diagnostik auf höchstem... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 44,710 | +8,94 % | Avidity Biosciences: BofA Securities erhöht Kursziel auf 65 US-Dollar | ||
TOURMALINE BIO | 47,600 | 0,00 % | Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen | DJ Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen
Von Adam Whittaker
DOW JONES--Novartis will das US-Biopharmaunternehmen Tourmaline Bio für rund 1,4 Milliarden US-Dollar... ► Artikel lesen | |
RAPPORT THERAPEUTICS | 23,750 | +2,37 % | Rapport Therapeutics, Inc.: Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures | Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving... ► Artikel lesen | |
MAZE THERAPEUTICS | 23,270 | -6,17 % | Maze Therapeutics, Inc.: Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria ... | Phase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for both intended indications of PKU and CKD Dose-dependent urinary amino acid... ► Artikel lesen | |
TANGO THERAPEUTICS | 6,530 | -4,39 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights | - First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors - - First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5... ► Artikel lesen | |
MINERALYS THERAPEUTICS | 37,060 | -0,32 % | Hedge Fund and Insider Trading News: Louis Bacon, Bill Ackman, Warren Buffett, Dan Loeb, Silver Point Capital, Starboard Value, Elliott Management, Mineralys Therapeutics Inc (MLYS), DuPont de Nemours Inc (DD), and More | ||
ENLIVEN THERAPEUTICS | 19,960 | +0,20 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update | Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks... ► Artikel lesen |